PRDM1 expression in T-cell lymphoma
| . | No. . | PRDM1 (%) . | IRF4 (%) . | Laser-microdissected cells . | ||
|---|---|---|---|---|---|---|
| PRDM1α (%) . | PRDM1β (%) . | IRF4 (%) . | ||||
| Histologic typing (World Health Organization classification) | ||||||
| Peripheral T-cell lymphoma | 23 | 10 (43.5) | 15 (65.2) | 14 (60.9) | 7 (30.4) | 15 (65.2) |
| Anaplastic large-cell lymphoma | 9 | 5 (55.6) | 8 (88.9) | 7 (77.8) | 4 (44.4) | 8 (88.9) |
| T/NK nasal-type lymphoma | 12 | 3 (25.0) | 8 (66.7) | 4 (33.3) | 2 (16.7) | 8 (66.7) |
| T-angioimmunoblastic lymphoma | 5 | 1 (20.0) | 2 (40.0) | 2 (40.0) | 1 (20.0) | 2 (40.0) |
| T-lymphoblastic lymphoma | 11 | 0 | 0 | 0 | 0 | 0 |
| Ann Arbor stage | ||||||
| I to II | 12 | 2 (16.7) | 6 (50.0) | 4 (33.3) | 0 | 6 (50.0) |
| III to IV | 48 | 17 (35.4) | 27 (56.3) | 23 (47.9) | 14 (29.2) | 27 (56.3) |
| No. of sites of extranodal involvement | ||||||
| 0 to 1 | 29 | 10 (34.5) | 18 (62.2) | 13 (44.8) | 6 (20.7) | 18 (62.2) |
| 2 to 3 | 31 | 9 (29.0) | 15 (48.4) | 14 (45.2) | 8 (25.8) | 15 (48.4) |
| Serum LDH level | ||||||
| Normal or lower | 23 | 9 (39.1) | 14 (60.9) | 10 (43.5) | 6 (26.1) | 14 (60.9) |
| Higher than normal | 37 | 10 (27.0) | 19 (51.4) | 17 (45.9) | 8 (21.6) | 19 (51.4) |
| IPI score | ||||||
| Low risk to intermediate low risk | 23 | 5 (21.7) | 13 (56.5) | 9 (39.1) | 2 (8.7) | 13 (56.5) |
| Intermediate high risk to high risk | 37 | 14 (37.8) | 20 (54.1) | 18 (48.6) | 12 (32.4) | 20 (54.1) |
| . | No. . | PRDM1 (%) . | IRF4 (%) . | Laser-microdissected cells . | ||
|---|---|---|---|---|---|---|
| PRDM1α (%) . | PRDM1β (%) . | IRF4 (%) . | ||||
| Histologic typing (World Health Organization classification) | ||||||
| Peripheral T-cell lymphoma | 23 | 10 (43.5) | 15 (65.2) | 14 (60.9) | 7 (30.4) | 15 (65.2) |
| Anaplastic large-cell lymphoma | 9 | 5 (55.6) | 8 (88.9) | 7 (77.8) | 4 (44.4) | 8 (88.9) |
| T/NK nasal-type lymphoma | 12 | 3 (25.0) | 8 (66.7) | 4 (33.3) | 2 (16.7) | 8 (66.7) |
| T-angioimmunoblastic lymphoma | 5 | 1 (20.0) | 2 (40.0) | 2 (40.0) | 1 (20.0) | 2 (40.0) |
| T-lymphoblastic lymphoma | 11 | 0 | 0 | 0 | 0 | 0 |
| Ann Arbor stage | ||||||
| I to II | 12 | 2 (16.7) | 6 (50.0) | 4 (33.3) | 0 | 6 (50.0) |
| III to IV | 48 | 17 (35.4) | 27 (56.3) | 23 (47.9) | 14 (29.2) | 27 (56.3) |
| No. of sites of extranodal involvement | ||||||
| 0 to 1 | 29 | 10 (34.5) | 18 (62.2) | 13 (44.8) | 6 (20.7) | 18 (62.2) |
| 2 to 3 | 31 | 9 (29.0) | 15 (48.4) | 14 (45.2) | 8 (25.8) | 15 (48.4) |
| Serum LDH level | ||||||
| Normal or lower | 23 | 9 (39.1) | 14 (60.9) | 10 (43.5) | 6 (26.1) | 14 (60.9) |
| Higher than normal | 37 | 10 (27.0) | 19 (51.4) | 17 (45.9) | 8 (21.6) | 19 (51.4) |
| IPI score | ||||||
| Low risk to intermediate low risk | 23 | 5 (21.7) | 13 (56.5) | 9 (39.1) | 2 (8.7) | 13 (56.5) |
| Intermediate high risk to high risk | 37 | 14 (37.8) | 20 (54.1) | 18 (48.6) | 12 (32.4) | 20 (54.1) |